Login to Your Account



SEEK's Immune-Boosting HIV Vaccine Jumping to Phase III

By Nuala Moran


Tuesday, July 19, 2011
LONDON – SEEK Ltd. has reached clinical proof of efficacy in a Phase Ib/II trial of its HIV-v vaccine, showing a 90 percent reduction in viral load in HIV-infected volunteers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription